Igalelo lethu elikhulu kukuba unyango olusisigxina ludibanisa izibonelelo ze-chemotherapy kunye ne-immunotherapy, kwaye ngokokuqala ngqa, ezi zimbini zidibene kwaye zisetyenziselwa unyango lwe-intratumoral ngokungenelela. Idibanisa unyango lwasekhaya kunye nehlabathi jikelele, kwaye inyusa ugxininiso kunye nexesha lesenzo sechiza ngokukhutshwa okuqhubekayo kwamachiza ngaphakathi kwethumba, elingadlali kuphela impembelelo ye-anticancer yendawo yamachiza e-chemotherapy, kodwa ithathela ingqalelo indima ye-systemic immunotherapy, ngaloo ndlela yenza ukusilela kolunye unyango, ibonelela ngeembono ezintsha kunye neendlela zonyango lomhlaza, ngakumbi kumathumba aphakathi kunye naphambili, ngakumbi ekunciphiseni ukuphindaphinda kwe-tumor ebaluleke kakhulu; Unyango lwe-UMPIC lunenzuzo yokusebenzisa ithumba njengomthombo we-antigen kunye nogonyo lwe-autologous, olukwahambelana nendlela yophuhliso lwe-Personalized Medicine. Kwaye ifakwe kwiklinikhi, i-hapten idityaniswe namachiza e-chemotherapy ukwenzela unyango oluqhubekayo lokukhululwa komhlaza we-pancreatic ugxininiso oluphambili, ngelixa lubangela umphumo we-distal, undoqo wayo kukubangela impendulo yomzimba, i-CD4 ehlobene ne-T-cell, i-CD8, i-DC, i-T kunye ne-NK iiseli, kunye ne-B-cell-related tumor autoantibodies: Antibodies ukuya kwi-P53, i-P16, i-Cmytac, i-Survic, i-HCC, i-HCC kunye nezinye i-oncogenes, eli lixesha lokuqala lokufumanisa ukuba i-T kunye ne-B zibandakanyeka kwi-immune response, kunye nemisebenzi yeklinikhi yempembelelo ye-distal kwaye olu nyango lukhethwe "Izikhokelo zeClinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (i-7th edition) iqulunqwe ngokudibeneyo yi-Chinese Anti-Cancer Association, i-National Clinical Medical Research Centre kunye ne-National Clinical Research Centre epapashwe kwi-National Clinical Research kunye neZiko loPhando lweSizwe. kwi Journal of Clinical Radiology, volume 43, number 19, 2024, 1636-1648.